Sp478
STATE OF THE ART: EMR VERSUS ESD IN THE MANAGEMENT OF DYSPLASTIC BARRETT’S AND ESOPHAGEAL ADENOCARCINOMA
Date
May 19, 2024
Presenter
Mayo Clinic
Tracks
Related Products
VALIDATION OF COPY NUMBER ABERRATION AND METHYLATED DNA MARKERS FOR DIFFERENTIATION OF NON-DYSPLASTIC BARRETT’S ESOPHAGUS FROM BARRETT’S ESOPHAGUS WITH HIGH GRADE DYSPLASIA AND ESOPHAGEAL ADENOCARCINOMA : A MULTICENTER STUDY
Endoscopic surveillance of Barrett’s esophagus (BE) is recommended to identify dysplasia (low grade [LGD], high grade [HGD]) or adenocarcinoma [EAC]) for endoscopic intervention. However, this paradigm is limited by sampling error and subtle endoscopic changes, leading to missed HGD and EAC…
EXTERNAL VALIDATION OF A DEEP LEARNING MODEL FOR WHOLE SLIDE IMAGE ANALYSIS IN THE HISTOLOGIC DIAGNOSIS OF DYSPLASTIC BARRETT’S ESOPHAGUS
Introduction: Shifts towards high-fat, low-fiber diets, may contribute to the rising incidence of esophageal adenocarcinoma (EAC). In mice high-fat diet promotes EAC, possibly through effects on the gut microbiome and the systemic bile acid pool…
DEVELOPMENT AND VALIDATION OF A MACHINE LEARNING (ML) BASED DECISION-MAKING TOOL TO DETERMINE RISK AND TIMING OF RECURRENCE OF BARRETT’S ESOPHAGUS (BE) NEOPLASIA AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY (EET)
Recent studies have described the durability of EET for BE-related neoplasia and the risk of neoplastic recurrence after achieving complete eradication of intestinal metaplasia (CE-IM). Current guidelines for endoscopic surveillance intervals post-EET are based on limited evidence…
